The Business Research Company’s global market reports are now updated with the latest market sizing information for the year 2023 and forecasted to 2032

The Business Research Company’s pediatric neuroblastoma treatment market report forecasts the pediatric neuroblastoma treatment market size to grow to $2.37 Billion by 2027, with a CAGR (compound annual growth rate) of more than 9%.

Learn More On The Pediatric Neuroblastoma Treatment Market Report 2023 – https://www.thebusinessresearchcompany.com/report/pediatric-neuroblastoma-treatment-global-market-report

Pediatric Neuroblastoma Treatment Market Size Forecast
The global pediatric neuroblastoma treatment market is expected to grow from $1.52 billion in 2022 to $1.67 billion in 2023 at a compound annual growth rate (CAGR) of 10.3%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The global pediatric neuroblastoma treatment market size is expected to reach $2.37 billion in 2027 at a CAGR of 9.1%.

North America held the largest pediatric neuroblastoma treatment market share.

Key Pediatric Neuroblastoma Treatment Market Driver ­– Rise In Number Of New Cases Of Pediatric Neuroblastoma
According to an article published in March 2023 by the American Society of Clinical Oncology (ASCO), a US-based organisation for oncology experts and physicians, neuroblastoma affects 700 to 800 children in the United States each year. Neuroblastoma accounts for 6% of all juvenile cancers in the United States. 90% of children under the age of five are affected by neuroblastoma. As a result, the growing number of new cases of paediatric neuroblastoma is propelling the paediatric neuroblastoma therapy market forward.

Request for A Sample Of The Global Pediatric Neuroblastoma Treatment Market Report:
https://www.thebusinessresearchcompany.com/sample.aspx?id=9924&type=smp

Key Pediatric Neuroblastoma Treatment Market Trend – Research And Development
To maintain their market position, major businesses in the paediatric neuroblastoma treatment market are focused on advanced research and development. Clarity Pharmaceuticals, an Australia-based radiopharmaceutical business, for example, stated in July 2020 that the 67Cu-SARTATETM trial for paediatric patients with neuroblastoma has begun at Memorial Sloan Kettering Cancer Centre (MSK) in New York City. The Peptide Receptor Radionuclide Therapy (PRRT) trial 67Cu-SARTATETM is for children with high-risk neuroblastoma. MSK is conducting a multi-center, open-label, dose-escalation, non-randomized Phase 1/2a theranostic clinical trial.

Pediatric Neuroblastoma Treatment Market Segment
1) By Treatment Type: Immunotherapy, Chemotherapy, Radiation Therapy, Other Treatment Types
2) By Risk Group: Low Risk, Intermediate Risk, High Risk
3) By End User: Hospitals, Specialty Clinics, Other End Users

Pediatric Neuroblastoma Treatment Market Major Players and Strategies
Major players in the pediatric neuroblastoma treatment market are United Therapeutics Corporation, APEIRON Biologics AG, Baxter International Inc., Cell Ectar Biosciences Inc., Pfizer Inc., MacroGenics Inc., Bayer AG, Provectus Biopharmaceuticals Inc., Sartorius AG, Y-mAbs Therapeutics Inc., Amgen Inc., Eli Lilly and Company, F. Hoffmann-La Roche AG, Clarity Pharmaceuticals, and CureSearch for Children’s Cancer.

Recordati S.p.A., an Italian pharmaceutical business, paid $824.28 million for EUSA Pharma (UK) Ltd. in March 2022. The acquisition will provide Recordati with a bigger array of medications for uncommon disorders. EUSA Pharma (UK) Ltd. is a specialist pharmaceutical firm established in the United Kingdom that specialises in paediatric neuroblastoma treatment.

The Pediatric Neuroblastoma Treatment Global Market Report 2023 covers regional data on pediatric neuroblastoma treatment market size, pediatric neuroblastoma treatment market trends and drivers, opportunities, strategies, and pediatric neuroblastoma treatment market competitor analysis. The countries covered in the pediatric neuroblastoma treatment market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, the UK, and the USA, and the major seven regions are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa.

Paediatric neuroblastoma treatment is a type of cancer or tumour treatment that affects the nerve system in children. Surgery, chemotherapy, radiation treatment, immunotherapy, and targeted therapy are commonly used to treat neuroblastoma.

View More Reports Related To The Pediatric Neuroblastoma Treatment Market –
Pediatric Vaccine Global Market Report 2023
Pediatric Imaging Global Market Report 2023
Polycystic Ovarian Syndrome Treatment Global Market Report 2023

Contact us at:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 3156230293
Asia +44 2071930708
Europe +44 2071930708
Email us at [email protected]

Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Found this article helpful? Share it on: